Overall, the results of the RELATIVITY‐047 trial demonstrate that co‐blockade of LAG‐3 and PD‐1 is an effective therapeutic strategy in melanoma and inaugurate LAG‐3 as the third T cell inhibitory pathway whose blockade is beneficial in the clinics. Here, PDCD1 is linked to melanoma.